Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034948 | 1.00 | DHODH (0.39) | DHODHCLK1MAP2K2MAP2K1LIPG | |
| SCHEMBL24349717 | 0.91 | MAP2K1 (0.44) | CLK1MAP2K2MAP2K1LIPGPIP4K2A | |
| SCHEMBL24350196 | 0.86 | ATM (0.44) | DHODHCLK1MAP2K2MAP2K1PIP4K2A | |
| SCHEMBL949141 | 0.84 | MAP2K1 (0.51) | DHODHCLK1MAP2K2MAP2K1 | |
| SCHEMBL30033040 | 0.84 | MAP2K1 (0.51) | DHODHCLK1MAP2K2MAP2K1 | |
| SCHEMBL30033664 | 0.83 | MAP2K1 (0.46) | MAP2K2MAP2K1 | |
| SCHEMBL20565713 | 0.83 | MAP2K1 (0.46) | MAP2K2MAP2K1 | |
| SCHEMBL26047332 | 0.82 | CLK1 (0.39) | CLK1MAP2K2MAP2K1LIPGPIP4K2A | |
| SCHEMBL20564982 | 0.81 | DHODH (0.39) | DHODHCLK1MAP2K2MAP2K1ATM | |
| SCHEMBL30034964 | 0.81 | DHODH (0.39) | DHODHCLK1MAP2K2MAP2K1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| EP-3883554-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883553-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3624795-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFlection Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213807-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | DHODH 3633/4885CLK1 3929/4885MAP2K2 3533/4885 |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | DHODH 2049/4885CLK1 1601/4885MAP2K2 37/4885 |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | DHODH 2085/4885CLK1 1596/4885MAP2K2 34/4885 |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | DHODH 2085/4885CLK1 1596/4885MAP2K2 34/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | DHODH 2049/4885CLK1 1601/4885MAP2K2 37/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | DHODH 4348/4885CLK1 2132/4885MAP2K2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.